一名 78 岁骨髓肿瘤患者存在 USP25::PDGFRA 基因融合。
A Novel USP25::PDGFRA Gene Fusion in a 78 Year Old Patient with a Myeloid Neoplasm.
机构信息
Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States.
Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States.
出版信息
Lab Med. 2022 Sep 1;53(5):e134-e138. doi: 10.1093/labmed/lmac010.
The World Health Organization category of myeloid/lymphoid neoplasms with eosinophilia and PDGFRA rearrangements is composed of a heterogeneous group of neoplasms that can present as a myeloproliferative neoplasm, acute myeloid leukemia, myeloid sarcoma, or lymphoblastic leukemia/lymphoma. The overall outcome of these neoplasms is favorable with imatinib therapy. Herein, we describe an adult female patient with a myeloid neoplasm accompanied by eosinophilia and a novel USP25::PDGFRA gene fusion.
世界卫生组织（WHO）分类中的伴嗜酸性粒细胞增多和 PDGFRA 重排的髓系/淋系肿瘤，是一组异质性肿瘤，可表现为骨髓增殖性肿瘤、急性髓系白血病、髓系肉瘤或淋巴母细胞白血病/淋巴瘤。这些肿瘤的总体预后良好，伊马替尼治疗有效。本文描述了一例伴嗜酸性粒细胞增多和 USP25::PDGFRA 基因融合的髓系肿瘤成年女性患者。
Zotero 插件